The U.S. Food and Drug Administration (FDA) has approved the Ebola Ervebo vaccine for the first time, and FDA experts say that while Ebola cases are rarely found in the U.S., vaccines are essential to prevent an Outbreak and prevent large-scale spread in the event of an outbreak, according tomedia reports. The vaccine, produced by drug giant Merck of the United States, was licensed a month ago by the European Union for the sale of the adult Ebola virus vaccine.
The vaccine was used to help the Democratic Republic of the Congo respond to the Ebola outbreak, and Ervebo has now arrived in the country for vaccination. Over the past five years, the Ebola outbreak in West Africa has resulted in more than 28,000 cases and 11,000 deaths.
The vaccine has been clinically tested in more than 900 cases, and trials have shown that the body does produce antibodies, with only a few injections of pain, swelling and redness, headache, fever, joint and muscle aches.
The vaccine itself was first developed by researchers at Canada’s National Microbiology Laboratory and then licensed to NewLink. Merck was authorized in 2014 and further developed. The vaccine is known to target Zaire (Zaire type), one of four Ebola virus types, which was the culprit in almost all subsequent human outbreaks when the Ebola virus was first detected in 1976.